<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83488">
  <stage>Registered</stage>
  <submitdate>31/12/2008</submitdate>
  <approvaldate>18/02/2009</approvaldate>
  <actrnumber>ACTRN12609000113257</actrnumber>
  <trial_identification>
    <studytitle>The comparison between topical terbinafine and placebo in the treatment of cutaneous  leishmaniasis</studytitle>
    <scientifictitle>The comparison between topical terbinafine and placebo in the treatment of cutaneous  leishmaniasis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>cutaneou leishmaniasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Topical terbinafine 2% cream twice daily until 10 weeks was applied on the cutaneous leishmaniasis lesions
+ intralesional  injection of glucantime (435 mg of sb5+, active antimony) once per week until 10 weeks</interventions>
    <comparator>placebo ( vaseline cream Mahan)  twice daily until 10 weeks was applied on the cutaneous leishmaniasis lesions
+ intralesional  injection of glucantime (435 mg of sb5+, active antimony) once per week until 10 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>size of induration with a transparent paper by an independed observer who is blind to the treatment options</outcome>
      <timepoint>the size of induration will be measures every 2 weeks week up to 10 weeks, 2 weeks and 3 months after the end of  treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>smear for leishman body</outcome>
      <timepoint>at the end of treatment, 2 weeks and 3 months after the end of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age&gt;2 years, the size of lesion&lt;3cm, the number of lesions&lt;4, the patients whom did not injected glucantim, the patinets whom did not receive any treatment for leishmaniasis within last month.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>pregnancy, lactation, the lesions  of articular area.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelops</concealment>
    <sequence>block randomization</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>88</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Kerman</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Kerman medical university</primarysponsorname>
    <primarysponsoraddress>Kerman  medical university,Kerman, Iran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Kerman medical university</fundingname>
      <fundingaddress>Kerman  medical university,Kerman, Iran</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Afzalipour hospital</sponsorname>
      <sponsoraddress>Afzalipour hospital,Kerman  medical university,Kerman, Iran</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Leishmaniasis is a parasitic disease  that is endemic in developing countries. The incidence of leishmaniasis is more than 400,000 cases  annually and the prevalence of all form of leishmaniasis is more than twelve millions.
Although cutaneous leishmaniasis (CL) is a self- healing disease , the duration of the disease is long and requeries several months and somtimes years before complete recovery , depending on the species of the infecting parasite . After recovery, a disfiguring scar can be left , which may destroy underlying structures like the nose or ear or cause psychological suffering of patients .
The first line drug for treatment of CL., according to WHO recommendation , is the pentavalent comounds such as meglomine antimoniate (Glucantime).
Other treatment for cutaneous leishmaniasis are intralesinal injection of meglomine antimonate, terbinafine , paramonycin ointment ,    and physical treatment including cryotherapy .the aim of this atudy is to determine the efficacy of topical terbinafine in the treatment of cutaneous leishmaniasis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ethical committee of Kerman medical university</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>k-85/33</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Saeedeh Farajzadeh</name>
      <address>Dermatology ward,Afzalipour hospital,Kerman,Iran</address>
      <phone>0913-341-4259</phone>
      <fax>0098-0341-322-2270</fax>
      <email>s_farajzadeh@kmu.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Armita shahesmaeili</name>
      <address>clinical research department,Afzalipour hospital,Kerman,Iran</address>
      <phone>0913-340-6291</phone>
      <fax>0098-0341-322-2270</fax>
      <email>a.shahesmaeili@gmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Armita shahesmaeili</name>
      <address>clinical research department,Afzalipour hospital,Kerman,Iran</address>
      <phone>0913-340-6291</phone>
      <fax>0098-0341-322-2270</fax>
      <email>a.shahesmaeili@gmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>